$0.191
-0.120 (-62.91%)At close
NKGN Comparative Benchmarking
In the context of the broader market, NKGN competes directly with industry leaders such as LOCL and GTI. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NKGN's gross margin of N/A stands against LOCL's 7.55% and GTI's -142.93%. Such benchmarking helps identify whether NKGen Biotech Inc is trading at a premium or discount relative to its financial performance.
Financials
FY2023Q4
0.00
Total Revenue
FY2024Q2
YoY:
+12.80%
-7.46M
Operating Profit
FY2024Q2
YoY:
+104.97%
-16.09M
Net Income after Tax
FY2024Q2
YoY:
+71.79%
-0.67
EPS - Diluted
FY2024Q2
YoY:
+8.42%
-6.01M
Free Cash Flow
FY2022Q4
76.62
Gross Profit Margin - %
FY2023Q2
-712.10K
FCF Margin - %
FY2022Q4
-34.74K
Net Margin - %
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.